News
EU approves Enspryng for neuromyelitis optica spectrum disorder.- Roche
Roche announced that the European Commission (EC) has approved Enspryng (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST).
Enspryng is the first and only NMOSD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.
The EC approval is supported by results from two Phase III studies, in which Enspryng showed robust and sustained efficacy in reducing the risk of relapse in people with AQP4-IgG seropositive NMOSD. AQP4-IgG are present in around 70-80% of people with NMOSD, who tend to experience a more severe disease course compared to those not expressing AQP4-IgG antibodies.
Condition: Neuromyelitis Optica
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins